Zurich Cantonal Bank
SPRO icon

Zurich Cantonal Bank’s Spero Therapeutics SPRO Stock Holding History

Zurich Cantonal Bank’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,950
Closed -$4K – 2900
2022
Q3 		$4K Hold
1,950
– – ﹤0.01% 2893
2022
Q2 		$1K Hold
1,950
– – ﹤0.01% 2888
2022
Q1 		$17K Sell
1,950
-1,276
-40% -$13.1K ﹤0.01% 2682
2021
Q4 		$52K Sell
3,226
-327
-9% -$5.19K ﹤0.01% 2724
2021
Q3 		$65K Buy
3,553
+94
+3% +$1.51K ﹤0.01% 2534
2021
Q2 		$48K Buy
3,459
+164
+5% +$2.29K ﹤0.01% 2458
2021
Q1 		$49K Buy
+3,295
New +$58K ﹤0.01% 2397

Other funds holding SPRO

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Zurich Cantonal Bank's SPRO Position: Q4 2022 in Review

Zurich Cantonal Bank sold out of Spero Therapeutics (SPRO) in Q4 2022, closing a stake of 1,950 shares — an estimated $4K sold.

Zurich Cantonal Bank first reported a position in SPRO in Q1 2021 and held it in 7 quarters. The position peaked at $65K in Q3 2021. 60 funds tracked by Wall St. Rank hold SPRO as of Q4 2022.

  • Zurich Cantonal Bank reported no remaining Spero Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Zurich Cantonal Bank sold 1,950 Spero Therapeutics shares in Q4 2022, an estimated $4K.
  • Zurich Cantonal Bank first reported a position in Spero Therapeutics in Q1 2021 and held it in 7 quarters.
  • Zurich Cantonal Bank's Spero Therapeutics position peaked at $65K in Q3 2021.
  • 60 funds tracked by Wall St. Rank held Spero Therapeutics as of Q4 2022.

Based on Zurich Cantonal Bank's 13F filing for Q4 2022, filed 1 Feb 2023.